The change of urinary 11-dehydro-thromboxane B2 and 2,3-dinor-6-keto- prostaglandin F1α in arteriogenic impotence

J. S N Lin, S. M C Lui, C. M. Chen, W. C. Chang

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Thromboxane A2 is a potent vasoconstrictor and a stimulus of platelet aggregation, which may contribute to hypercoagulability. The prostacyclin, prostaglandin I2, has exactly the opposite effect. Measurement of the major urinary metabolites, 11-dehydro-thromboxane B2 and 2,3-dinor-6-keto- prostaglandin F1α (prostaglandin F1α) by radioimmunoassay can accurately reflect in vivo the biosynthesis of thromboxane A2 and prostaglandin I2, respectively. Group 1 consisted of 60 patients less than 50 years old. The mean urinary 11-dehydro-thromboxane B2 level of 3 patients with arteriogenic impotence was significantly greater than that of the 57 control volunteers: 2.66 ± 0.65 versus 1.74 ± 0.56 (plus or minus standard deviation) ng./mg. creatinine (p = 0.008). The prostaglandin F1α levels for the patients and controls were 32.74 ± 8.45 and 37.58 ± 16.55 ng./mg. creatinine, respectively, which was not significantly different (p >0.05). Group 2 consisted of 96 patients 50 years old or older. The 11-dehydro-thromboxane B2 concentration in the urine was 1.83 ± 0.58, 2.54 ± 1.12 and 1.91 ± 0.73 ng./mg. creatinine in the 47 normal control volunteers, 20 patients with arteriogenic impotence and 29 with arteriogenic impotence plus intracavernous injection of 20 μg. prostaglandin E1, respectively. The arteriogenic impotence group showed the significantly highest level among the 3 groups (p = 0.0025). Also, the urinary prostaglandin F1α levels in these patients were 45.71 ± 36.3, 57.71 ± 35.53 and 59.30 ± 45.08 ng./mg. creatinine, respectively, which was not significantly different (p >0.05). For the 13 patients with arteriogenic impotence (group 3) we compared the urinary 11- dehydro-thromboxane B2 and prostaglandin F1α levels before and after intracavernous injection of prostaglandin E1 by using a paired t test. The results showed that the change in 11-dehydro-thromboxane B2 levels was 2.78 ± 1.09 versus 1.99 ± 0.75 ng./mg. creatinine, which was significantly different (p = 0.005), whereas that for prostaglandin F1α was 62.30 ± 40.41 versus 58.86 ± 44.26 ng./mg. creatinine, with no significant difference (p >0.05). Our findings suggest that urinary 11-dehydro-thromboxane B2 may have an important role in the diagnosis and treatment of arteriogenic impotence.

Original languageEnglish
Pages (from-to)311-313
Number of pages3
JournalJournal of Urology
Volume148
Issue number2 I
Publication statusPublished - 1992
Externally publishedYes

Fingerprint

Vasculogenic Impotence
Creatinine
Epoprostenol
Thromboxane A2
Alprostadil
Injections
Thrombophilia
Vasoconstrictor Agents
prostaglandin F1
11-dehydro-2,3-dinor-thromboxane B2
Platelet Aggregation
Radioimmunoassay
Volunteers
Healthy Volunteers
11-dehydro-thromboxane B2
Urine

Keywords

  • impotence
  • penile erection
  • prostaglandins
  • thromboxane B2

ASJC Scopus subject areas

  • Urology

Cite this

The change of urinary 11-dehydro-thromboxane B2 and 2,3-dinor-6-keto- prostaglandin F1α in arteriogenic impotence. / Lin, J. S N; Lui, S. M C; Chen, C. M.; Chang, W. C.

In: Journal of Urology, Vol. 148, No. 2 I, 1992, p. 311-313.

Research output: Contribution to journalArticle

@article{ddeeaaa7fe3b4089a30df6810af929e5,
title = "The change of urinary 11-dehydro-thromboxane B2 and 2,3-dinor-6-keto- prostaglandin F1α in arteriogenic impotence",
abstract = "Thromboxane A2 is a potent vasoconstrictor and a stimulus of platelet aggregation, which may contribute to hypercoagulability. The prostacyclin, prostaglandin I2, has exactly the opposite effect. Measurement of the major urinary metabolites, 11-dehydro-thromboxane B2 and 2,3-dinor-6-keto- prostaglandin F1α (prostaglandin F1α) by radioimmunoassay can accurately reflect in vivo the biosynthesis of thromboxane A2 and prostaglandin I2, respectively. Group 1 consisted of 60 patients less than 50 years old. The mean urinary 11-dehydro-thromboxane B2 level of 3 patients with arteriogenic impotence was significantly greater than that of the 57 control volunteers: 2.66 ± 0.65 versus 1.74 ± 0.56 (plus or minus standard deviation) ng./mg. creatinine (p = 0.008). The prostaglandin F1α levels for the patients and controls were 32.74 ± 8.45 and 37.58 ± 16.55 ng./mg. creatinine, respectively, which was not significantly different (p >0.05). Group 2 consisted of 96 patients 50 years old or older. The 11-dehydro-thromboxane B2 concentration in the urine was 1.83 ± 0.58, 2.54 ± 1.12 and 1.91 ± 0.73 ng./mg. creatinine in the 47 normal control volunteers, 20 patients with arteriogenic impotence and 29 with arteriogenic impotence plus intracavernous injection of 20 μg. prostaglandin E1, respectively. The arteriogenic impotence group showed the significantly highest level among the 3 groups (p = 0.0025). Also, the urinary prostaglandin F1α levels in these patients were 45.71 ± 36.3, 57.71 ± 35.53 and 59.30 ± 45.08 ng./mg. creatinine, respectively, which was not significantly different (p >0.05). For the 13 patients with arteriogenic impotence (group 3) we compared the urinary 11- dehydro-thromboxane B2 and prostaglandin F1α levels before and after intracavernous injection of prostaglandin E1 by using a paired t test. The results showed that the change in 11-dehydro-thromboxane B2 levels was 2.78 ± 1.09 versus 1.99 ± 0.75 ng./mg. creatinine, which was significantly different (p = 0.005), whereas that for prostaglandin F1α was 62.30 ± 40.41 versus 58.86 ± 44.26 ng./mg. creatinine, with no significant difference (p >0.05). Our findings suggest that urinary 11-dehydro-thromboxane B2 may have an important role in the diagnosis and treatment of arteriogenic impotence.",
keywords = "impotence, penile erection, prostaglandins, thromboxane B2",
author = "Lin, {J. S N} and Lui, {S. M C} and Chen, {C. M.} and Chang, {W. C.}",
year = "1992",
language = "English",
volume = "148",
pages = "311--313",
journal = "Journal of Urology",
issn = "0022-5347",
publisher = "Elsevier Inc.",
number = "2 I",

}

TY - JOUR

T1 - The change of urinary 11-dehydro-thromboxane B2 and 2,3-dinor-6-keto- prostaglandin F1α in arteriogenic impotence

AU - Lin, J. S N

AU - Lui, S. M C

AU - Chen, C. M.

AU - Chang, W. C.

PY - 1992

Y1 - 1992

N2 - Thromboxane A2 is a potent vasoconstrictor and a stimulus of platelet aggregation, which may contribute to hypercoagulability. The prostacyclin, prostaglandin I2, has exactly the opposite effect. Measurement of the major urinary metabolites, 11-dehydro-thromboxane B2 and 2,3-dinor-6-keto- prostaglandin F1α (prostaglandin F1α) by radioimmunoassay can accurately reflect in vivo the biosynthesis of thromboxane A2 and prostaglandin I2, respectively. Group 1 consisted of 60 patients less than 50 years old. The mean urinary 11-dehydro-thromboxane B2 level of 3 patients with arteriogenic impotence was significantly greater than that of the 57 control volunteers: 2.66 ± 0.65 versus 1.74 ± 0.56 (plus or minus standard deviation) ng./mg. creatinine (p = 0.008). The prostaglandin F1α levels for the patients and controls were 32.74 ± 8.45 and 37.58 ± 16.55 ng./mg. creatinine, respectively, which was not significantly different (p >0.05). Group 2 consisted of 96 patients 50 years old or older. The 11-dehydro-thromboxane B2 concentration in the urine was 1.83 ± 0.58, 2.54 ± 1.12 and 1.91 ± 0.73 ng./mg. creatinine in the 47 normal control volunteers, 20 patients with arteriogenic impotence and 29 with arteriogenic impotence plus intracavernous injection of 20 μg. prostaglandin E1, respectively. The arteriogenic impotence group showed the significantly highest level among the 3 groups (p = 0.0025). Also, the urinary prostaglandin F1α levels in these patients were 45.71 ± 36.3, 57.71 ± 35.53 and 59.30 ± 45.08 ng./mg. creatinine, respectively, which was not significantly different (p >0.05). For the 13 patients with arteriogenic impotence (group 3) we compared the urinary 11- dehydro-thromboxane B2 and prostaglandin F1α levels before and after intracavernous injection of prostaglandin E1 by using a paired t test. The results showed that the change in 11-dehydro-thromboxane B2 levels was 2.78 ± 1.09 versus 1.99 ± 0.75 ng./mg. creatinine, which was significantly different (p = 0.005), whereas that for prostaglandin F1α was 62.30 ± 40.41 versus 58.86 ± 44.26 ng./mg. creatinine, with no significant difference (p >0.05). Our findings suggest that urinary 11-dehydro-thromboxane B2 may have an important role in the diagnosis and treatment of arteriogenic impotence.

AB - Thromboxane A2 is a potent vasoconstrictor and a stimulus of platelet aggregation, which may contribute to hypercoagulability. The prostacyclin, prostaglandin I2, has exactly the opposite effect. Measurement of the major urinary metabolites, 11-dehydro-thromboxane B2 and 2,3-dinor-6-keto- prostaglandin F1α (prostaglandin F1α) by radioimmunoassay can accurately reflect in vivo the biosynthesis of thromboxane A2 and prostaglandin I2, respectively. Group 1 consisted of 60 patients less than 50 years old. The mean urinary 11-dehydro-thromboxane B2 level of 3 patients with arteriogenic impotence was significantly greater than that of the 57 control volunteers: 2.66 ± 0.65 versus 1.74 ± 0.56 (plus or minus standard deviation) ng./mg. creatinine (p = 0.008). The prostaglandin F1α levels for the patients and controls were 32.74 ± 8.45 and 37.58 ± 16.55 ng./mg. creatinine, respectively, which was not significantly different (p >0.05). Group 2 consisted of 96 patients 50 years old or older. The 11-dehydro-thromboxane B2 concentration in the urine was 1.83 ± 0.58, 2.54 ± 1.12 and 1.91 ± 0.73 ng./mg. creatinine in the 47 normal control volunteers, 20 patients with arteriogenic impotence and 29 with arteriogenic impotence plus intracavernous injection of 20 μg. prostaglandin E1, respectively. The arteriogenic impotence group showed the significantly highest level among the 3 groups (p = 0.0025). Also, the urinary prostaglandin F1α levels in these patients were 45.71 ± 36.3, 57.71 ± 35.53 and 59.30 ± 45.08 ng./mg. creatinine, respectively, which was not significantly different (p >0.05). For the 13 patients with arteriogenic impotence (group 3) we compared the urinary 11- dehydro-thromboxane B2 and prostaglandin F1α levels before and after intracavernous injection of prostaglandin E1 by using a paired t test. The results showed that the change in 11-dehydro-thromboxane B2 levels was 2.78 ± 1.09 versus 1.99 ± 0.75 ng./mg. creatinine, which was significantly different (p = 0.005), whereas that for prostaglandin F1α was 62.30 ± 40.41 versus 58.86 ± 44.26 ng./mg. creatinine, with no significant difference (p >0.05). Our findings suggest that urinary 11-dehydro-thromboxane B2 may have an important role in the diagnosis and treatment of arteriogenic impotence.

KW - impotence

KW - penile erection

KW - prostaglandins

KW - thromboxane B2

UR - http://www.scopus.com/inward/record.url?scp=0026712294&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026712294&partnerID=8YFLogxK

M3 - Article

C2 - 1635125

AN - SCOPUS:0026712294

VL - 148

SP - 311

EP - 313

JO - Journal of Urology

JF - Journal of Urology

SN - 0022-5347

IS - 2 I

ER -